BRPI0412581A - dispersible formulation of an anti-inflammatory agent - Google Patents

dispersible formulation of an anti-inflammatory agent

Info

Publication number
BRPI0412581A
BRPI0412581A BRPI0412581-9A BRPI0412581A BRPI0412581A BR PI0412581 A BRPI0412581 A BR PI0412581A BR PI0412581 A BRPI0412581 A BR PI0412581A BR PI0412581 A BRPI0412581 A BR PI0412581A
Authority
BR
Brazil
Prior art keywords
inflammatory agent
dispersible formulation
relates
formulation
organ
Prior art date
Application number
BRPI0412581-9A
Other languages
Portuguese (pt)
Inventor
Nancy Jean Britten
Niki Ann Waldron
Jeffrey Lynn Watts
John Walter Hallberg
John William Ii Burns
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BRPI0412581A publication Critical patent/BRPI0412581A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"FORMULAçãO DISPERSáVEL DE UM AGENTE ANTIINFLAMATóRIO". A presente invenção refere-se a um método que é provido para o tratamento e/ou a prevenção de uma condição inflamatória em um órgão contendo fluido e que tenha um orifício natural para o exterior, tal como o úbere de um animal que produza leite, ou a orelha de um sujeito. A invenção também refere-se a uma composição farmacêutica dispersável adequada para infusão no órgão consoante o método da invenção, e a um processo para se preparar uma tal composição."DISPOSAL FORMULATION OF AN ANTI-INFLAMMATORY AGENT". The present invention relates to a method which is provided for treating and / or preventing an inflammatory condition in a fluid-containing organ and having a natural outward orifice such as the udder of a milk-producing animal. or a subject's ear. The invention also relates to a dispersible pharmaceutical composition suitable for organ infusion according to the method of the invention, and a process for preparing such a composition.

BRPI0412581-9A 2003-07-31 2004-07-19 dispersible formulation of an anti-inflammatory agent BRPI0412581A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49212103P 2003-07-31 2003-07-31
PCT/IB2004/002461 WO2005009436A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
BRPI0412581A true BRPI0412581A (en) 2006-09-19

Family

ID=34103027

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412581-9A BRPI0412581A (en) 2003-07-31 2004-07-19 dispersible formulation of an anti-inflammatory agent

Country Status (14)

Country Link
EP (1) EP1651210A1 (en)
JP (1) JP2007500691A (en)
KR (1) KR100780983B1 (en)
CN (1) CN1829510A (en)
AU (1) AU2004258745A1 (en)
BR (1) BRPI0412581A (en)
CA (1) CA2533101A1 (en)
CO (1) CO5650245A2 (en)
IL (1) IL172735A0 (en)
MX (1) MXPA06001288A (en)
NO (1) NO20060982L (en)
RU (1) RU2319508C2 (en)
WO (1) WO2005009436A1 (en)
ZA (1) ZA200600096B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081406A1 (en) 2006-12-20 2008-10-17 Schering Plough Ltd PHARMACEUTICAL COMPOSITIONS OF FLUNIXIN
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
UA111147C2 (en) 2009-11-11 2016-04-11 Байєр Б.В. METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF EXTERNAL OTITIS
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
PL2366408T3 (en) * 2010-03-01 2013-01-31 Salvat Lab Sa Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
RU2486905C1 (en) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Method of treating mastitis in animals
CN102784161A (en) * 2012-08-01 2012-11-21 张吉川 Specific ear drops for treating acute/chronic tympanitis
ES2829904T3 (en) * 2013-01-14 2021-06-02 Infirst Healthcare Ltd Solid solution compositions and use in severe pain
WO2014117999A1 (en) * 2013-02-04 2014-08-07 Biocopea Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
LV15071B (en) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Composition for treatment of subclinical mastitis in cows
WO2017024282A1 (en) * 2015-08-05 2017-02-09 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
KR101738815B1 (en) * 2015-08-27 2017-05-23 심민보 Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus comprising platelet-rich plasma and method using the same
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
WO2019191547A1 (en) * 2018-03-29 2019-10-03 Yale University Novel fully synthetic and semisynthetic pleuromutilin derivatives as new antibiotics and their preparation
RU2749857C1 (en) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Method for combatting otitis media and otitis externa
RU2751697C1 (en) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Remedy for treatment of otitis of external auditory canal in dogs
KR102461699B1 (en) * 2021-05-21 2022-11-03 현대약품 주식회사 Gargle solution with improved stability comprising benzidamine hydrochloride
WO2023101418A1 (en) * 2021-12-03 2023-06-08 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus
KR20230084418A (en) * 2021-12-03 2023-06-13 (주)인비보텍 Composition for preventing or treating hearing loss or tinnitus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
NZ295170A (en) * 1994-10-26 1999-02-25 Novartis Ag Topical pharmaceutical compositions comprising a fk506 class compound, an unsaturated fatty alcohol, water and diether alcohol, alkanediol or ether diol as a solvent
PT782448E (en) * 1995-06-06 2002-07-31 Bayer Ag NON-IRRITATING, NON-OTOTOXIC ANTIBACTERIAL OTIC FORMULATIONS
DZ2479A1 (en) * 1997-05-05 2003-02-01 Pfizer Anti-inflammatory selective co-2 inhibitor compounds and pharmaceutical compositions containing them.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
IL152792A0 (en) * 2000-06-08 2003-06-24 Univ Texas Heterocycle derivatives and methods of use
JP2004501166A (en) * 2000-06-16 2004-01-15 ハーキュリーズ・インコーポレーテッド Chemically modified peptides, compositions, and methods of manufacture and use
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
WO2002022171A2 (en) * 2000-09-12 2002-03-21 Pharmacia & Upjohn Company Pharmaceutical composition having specific water activity
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
RU2006101628A (en) 2006-08-27
AU2004258745A1 (en) 2005-02-03
EP1651210A1 (en) 2006-05-03
WO2005009436A1 (en) 2005-02-03
ZA200600096B (en) 2007-02-28
WO2005009436A8 (en) 2005-05-06
RU2319508C2 (en) 2008-03-20
KR100780983B1 (en) 2007-11-30
KR20060031873A (en) 2006-04-13
JP2007500691A (en) 2007-01-18
NO20060982L (en) 2006-05-02
CO5650245A2 (en) 2006-06-30
MXPA06001288A (en) 2006-04-11
CA2533101A1 (en) 2005-02-03
CN1829510A (en) 2006-09-06
IL172735A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
BRPI0412581A (en) dispersible formulation of an anti-inflammatory agent
BRPI0408559A (en) dispersible pharmaceutical compositions for the treatment of mastitis and optical disorders
BRPI0408556A (en) dispersibly formulations of an anti-inflammatory agent
BRPI0414320A (en) skin care composition
BR0317747A (en) Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment
BR9914638A (en) Compound, method for its preparation, pharmaceutical composition, use of a compound, and method for the treatment of a disorder or disease in the body of a living animal
BRPI0407375A (en) Methods for treating pain by administering a neural growth factor antagonist and a nsaid and compositions containing same
ATE396973T1 (en) BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0512583A (en) compositions and methods of producing same, releasing active agent into and through the epidermis tissue of a person or animal and treating a patient suffering from onychomycosis, nail psoriasis and infections
BR0308854A (en) Substituted benzazoles and their uses as raf kinase inhibitors
AR029462A1 (en) DERIVATIVES OF THE PICOLINIC ACID, PROCEDURE TO PREPARE THEM AND COMPOSITIONS FORMED WITH SUCH DERIVATIVES AS AN ACTIVE AGENT, PREVENTIVE OR CURE PROCEDURES AGAINST PHYTO-PATHOGEN FUNGI, PREVENTIVE METHODS OR TREATMENT OF WOOD FOR CONSTRUCTION USING AND SUCH COMPOSITIONS
BRPI0513573A (en) protection method
BRPI0618374A2 (en) use of a pharmaceutically acceptable compound or derivative thereof, methods for killing clinically latent microorganisms in a mammal, for treating or preventing a microbial infection in a mammal, for sterilizing an object, for preserving an inorganic or organic material, for treating a disease , to reduce the dose of conventional antimicrobial agent required to treat a microbial infection and to treat a protozoan disease in a mammal, combined product, formulation, use of a combined product, compound, and process for preparing it.
BRPI0516077A (en) antimicrobial compositions comprising a natural agent selected from gallic acid, eucalipotol, naringin, a jasminic acid compound and any combination thereof
PT99597B (en) METHOD FOR THE PREPARATION OF HYDROXAMIC ACID DERIVATIVES THAT INHIBITS LIPOXYGENASE
ECSP088863A (en) COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND / OR SCHIZOPHRENIA
DK1392329T3 (en) Use of sulodexide for the treatment of inflammatory bowel disease
SE8600501L (en) PREPARATION FOR TREATMENT OF NAIL FUNGI AND SEBOROUS ECSC
BR9813811A (en) "pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only a single surfactant"
MXPA02012407A (en) Sprayable wound care compositions.
US20070264362A1 (en) Method and composition for treating ear inflammation caused by dry ear
BR0011225A (en) Agent to treat dry eyes, its method and use
AR001790A1 (en) Transdermal patch formulations for treating modeled muscarinic receptor conditions
WO1999062459A3 (en) Agents and methods for protection, treatment and repair of connective tissue
BRPI0412923A (en) Dispersible pharmaceutical composition for the treatment of mastitis and optical disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.